Enzyme Replacement Therapy Market Growth, Size, Trends Analysis - By Enzyme Type, By Indication, By Route of Administration, By End-User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Enzyme Replacement Therapy Market Introduction and Overview

According to SPER market research, 'Global Enzyme Replacement Therapy Market Size- By Enzyme Type, By Indication, By Route of Administration, By End-User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Enzyme Replacement Therapy Market is predicted to reach 25.7 billion by 2034 with a CAGR of 9.25%.

Enzyme replacement therapy (ERT) is used to replace a missing or defective enzyme in a person suffering from hereditary enzyme deficiency syndrome. It restores the patient's depleted enzymes via the intravenous (IV) or oral route of delivery. People widely accept the IV approach, which involves injecting the replacement enzyme straight into the bloodstream via a regulated trickle of fluids.

Restraints: The high cost of therapy is a key barrier to the enzyme replacement therapy business, affecting patients, healthcare systems, and pharmaceutical companies. While ERTs have proven to be beneficial in treating rare genetic illnesses and enzyme deficiencies, their high cost presents a hurdle. These medicines' high cost can present barriers to access, particularly for patients without adequate insurance coverage or in regions with limited healthcare resources.

Scope of the Report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered Analysis By Enzyme Type, By Indication, By Route of Administration, By End User.

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa.

Companies Covered

Shire Plc, Sanofi S.A, Biomarin Pharmaceutical Inc, AbbVie, Alexion Pharmaceuticals Inc, Allergan plc, Horizon Pharma Public Limited Company, Actelion (Janssen), Recordati Rare Diseases, Protalix Biotherapeutics.

Enzyme Replacement Therapy Market Segmentation:

By Enzyme Type: Based on the Enzyme Type, Global Enzyme Replacement Therapy Market is segmented as; Imiglucerase, Agalsidase beta, Taliglucerase, Velaglucerase alfa, Laronidase, Alglucosidase alfa, Galsulfase, Idursulfase, Pancreatic enzymes, Pegademase, Other enzyme types.

By Indication: Based on the Indication, Global Enzyme Replacement Therapy Market is segmented as; Gaucher disease, Fabry disease, Pompe disease, Plasma cell disorders, SCID, Mucopolysaccharidosis, MPS I Hurler, Hurler Scheie and Scheie, MPS II Hunter, MPS III Sanfilippo, Other mucopolysaccharidosis, other indications.

By Route of Administration: Based on the Route of Administration, Global Enzyme Replacement Therapy Market is segmented as; Parenteral, Oral.

By End-User: Based on the End User, Global Enzyme Replacement Therapy Market is segmented as; Hospitals, Infusion centers, other end-users.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: HLCA2540

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Enzyme Replacement Therapy Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Enzyme Replacement Therapy Market

7. Global Enzyme Replacement Therapy Market, By Enzyme Type (USD Million) 2021-2034

7.1. Imiglucerase
7.2. Agalsidase beta
7.3. Taliglucerase
7.4. Velaglucerase alfa
7.5. Laronidase
7.6. Alglucosidase alfa
7.7. Galsulfase
7.8. Idursulfase
7.9. Pancreatic enzymes
7.10. Pegademase
7.11. Other enzyme types

8. Global Enzyme Replacement Therapy Market, By Indication (USD Million) 2021-2034

8.1. Gaucher disease
8.2. Fabry disease
8.3. Pompe disease
8.4. Plasma cell disorders
8.5. SCID
8.6. Mucopolysaccharidosis (MPS)
8.7. MPS I - Hurler, Hurler Scheie and Scheie
8.8. MPS II - Hunter
8.9. MPS III - Sanfilippo
8.10. Other mucopolysaccharidosis
8.11. Other indications

9. Global Enzyme Replacement Therapy Market, By Route of Administration (USD Million) 2021-2034

9.1. Oral
9.2. Parenteral

10. Global Enzyme Replacement Therapy Market, By End-User (USD Million) 2021-2034

10.1. Hospitals
10.2. Infusion centers
10.3. Other end-users

11. Global Enzyme Replacement Therapy Market, (USD Million) 2021-2034

11.1. Global Enzyme Replacement Therapy Market Size and Market Share

12. Global Enzyme Replacement Therapy Market, By Region, (USD Million) 2021-2034

12.1. Asia-Pacific
- 12.1.1. Australia
- 12.1.2. China
- 12.1.3. India
- 12.1.4. Japan
- 12.1.5. South Korea
- 12.1.6. Rest of Asia-Pacific
12.2. Europe
- 12.2.1. France
- 12.2.2. Germany
- 12.2.3. Italy
- 12.2.4. Spain
- 12.2.5. United Kingdom
- 12.2.6. Rest of Europe
12.3. Middle East and Africa
- 12.3.1. Kingdom of Saudi Arabia
- 12.3.2. United Arab Emirates
- 12.3.3. Qatar
- 12.3.4. South Africa
- 12.3.5. Egypt
- 12.3.6. Morocco
- 12.3.7. Nigeria
- 12.3.8. Rest of Middle-East and Africa
12.4. North America
- 12.4.1. Canada
- 12.4.2. Mexico
- 12.4.3. United States
12.5. Latin America
- 12.5.1. Argentina
- 12.5.2. Brazil
- 12.5.3. Rest of Latin America

13. Company Profile

13.1. Shire Plc
- 13.1.1. Company details
- 13.1.2. Financial outlook
- 13.1.3. Product summary
- 13.1.4. Recent developments
13.2. Sanofi S.A
- 13.2.1. Company details
- 13.2.2. Financial outlook
- 13.2.3. Product summary
- 13.2.4. Recent developments
13.3. Biomarin Pharmaceutical Inc
- 13.3.1. Company details
- 13.3.2. Financial outlook
- 13.3.3. Product summary
- 13.3.4. Recent developments
13.4. AbbVie
- 13.4.1. Company details
- 13.4.2. Financial outlook
- 13.4.3. Product summary
- 13.4.4. Recent developments
13.5. Alexion Pharmaceuticals Inc
- 13.5.1. Company details
- 13.5.2. Financial outlook
- 13.5.3. Product summary
- 13.5.4. Recent developments
13.6. Allergan plc
- 13.6.1. Company details
- 13.6.2. Financial outlook
- 13.6.3. Product summary
- 13.6.4. Recent developments
13.7. Horizon Pharma Public Limited Company
- 13.7.1. Company details
- 13.7.2. Financial outlook
- 13.7.3. Product summary
- 13.7.4. Recent developments
13.8. Actelion (Janssen)
- 13.8.1. Company details
- 13.8.2. Financial outlook
- 13.8.3. Product summary
- 13.8.4. Recent developments
13.9. Recordati Rare Diseases
- 13.9.1. Company details
- 13.9.2. Financial outlook
- 13.9.3. Product summary
- 13.9.4. Recent developments
13.10. Protalix Biotherapeutics
- 13.10.1. Company details
- 13.10.2. Financial outlook
- 13.10.3. Product summary
- 13.10.4. Recent developments
13.11. Others